Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2020 · 10-Q
Revenue—
Net Income-$2.03M-$2.03MN/M vs Q1 2019 EPS Diluted-$0.03-$0.03N/M vs Q1 2019 Operating Cash Flow-$1,111,195N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed Jun 29, 2020 · 90 d after period end